Compare Amylx Pharmaceuticals Inc (AMLX) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Expeditors International of Wshngtn Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.29 (market cap $1.98B), while Expeditors International of Wshngtn Inc trades at $176.29 (market cap $22.50B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 11.4× Amylx Pharmaceuticals Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.94% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EXPD | |
|---|---|---|
Market Cap | $1.98B | $22.50B |
Sector | Health | Industrials |
52-Week High | $18.70 | $172.02 |
52-Week Low | $7.64 | $111.37 |
Enterprise Value | $1.70B | $21.75B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
EXPD trades at $172.02, near its R1 resistance of $173, with a bullish technical outlook supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.71 surpassing the $1.33 expectation. Revenue growth remains steady, reaching $11.07B in 2025, while maintaining strong profitability with a 36.59% ROE. Recent news highlights momentum from e-commerce demand and strategic focus on supply chain management.
The stock presents growth potential driven by earnings momentum and solid fundamentals, but faces headwinds from analyst skepticism (only 12% buy ratings) and valuation concerns with a P/E of 27.79 above industry averages. Key risks include freight market volatility and geopolitical supply chain pressures. The consensus price target of $159 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
